News

Halaven is a non-taxane, microtubule dynamics inhibitor that is a synthetic analog of halichondrin B, a natural product that was isolated from the marine sponge Halichondria okadai. Halaven

As per the agreement Servier will engage BioInvent to screen its proprietary n-CoDeR library for antibodies specific to the undisclosed target. Servier will also have access to BioInvent’s

The 390-patient study will compare the safety and effectiveness of HA-Irinotecan with irinotecan in a double blind trial in second and third line metastatic colorectal cancer patients (mCRC).

MacuCLEAR has also entered into a strategic partnership with a Pacific Rim pharmaceutical partner and investor to finance clinical costs, bridging studies and regulatory development for MC-1101 in

Genentech will make use of Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target. Vernalis CEO Ian Garland said the company is happy that Genentech chose

As per the agreement Vifor Pharma is granted an exclusive license for the Isotechnika’s drug, voclosporin, to treat lupus and all proteinuric nephrology indications (the Vifor Pharma License).

The last and third module of the application is backed by the findings from the final phase of clinical testing, which involved the use of the OraQuick Rapid

The monoclonal antibody will be engineered by GBI’s collaborative partner, and then GBI will evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for

The Phase 2 ZP-204 study is a five arm dose escalation study in which up to 12 women with diagnosed endometriosis or uterine fibroids were randomized to 1,